Good effort there love the autobiography (totally unverifiable of course).
BUT your post is superficial at best.
MSB isn't relying on the Covid19 space. Plus it's well recognised there will need to be a range of measures to deal with that virus. It's manifesting in various and dangerous ways. It's absurd to point to one company and imply that it's got a losing strategy because it's not got the entire one stop solution for a hugely complex public health problem.
(Keep it real). CSL is in the space as you put it.
MSB? It's not a one-trick pony anyway. Did you not notice other applications which are expected to be approved by the FDA this year?. ie. in biotech timeframes...soonish?
Apart from the fact that MSB is already administering the therapies for Covid19 under compassionate use.
Maybe you didn't notice the families of patents, including the manufacturing process.
All this and more....Slipped your mind?
MSB Price at posting:
$3.54 Sentiment: Buy Disclosure: Held
(20min delay)